International Journal of Medicine and Pharmaceutical Research
CODEN (USA): IJCPNH | ISSN: 2321-2624
Journal Home Page: www.pharmaresearchlibrary.com/ijmpr

Method development and validation for the simultaneous estimation of Talazoparib and Pitavastatin in bulk and tablet dosage form by using RP-HPLC in biorelevant dissolution media

Agaiah Goud Bairi[*1], Parameshwar Aleti[2]

[1]*Department of Pharmaceutics, SRR College of Pharmaceutical Sciences, Elkathurthi, Telangana, India*
[2]*Department of Pharmaceutical Analysis, SRR College of Pharmaceutical Sciences, Elkathurthi, Telangana, India*

A B S T R A C T

The primary purpose of current study is to establish and validate a unique, specific, precise, fast and economic stability – suggesting an isocratic opposite liquid chromatoographic approach in large-scale and commercialised formulations for the quantitative measurement of Talazoparib. An estimation of medication for this pharmacological dose is provided with a cellular composition section Methanol: Acetate Buffer (ph-four.2) (40: 60 v/v) when completed with the Inertsil ODS (4.6mmx250mm, 5µm) when it is stored on the temperature of 35°C.The flow rate was replaced by 1.zero ml/min, the effluents were monitored by a PDA-detector at a wavelength of 225 nm. Talazoparib retention time was established accordingly at 3.622min. With the ICH recommendations for excellent analytical parameters, validation of the method is steadily accomplished. The procedure for Talazoparib was shown to be linear in a range of 60-140µg/ml. The established approach has shown to be replicable at a percent RSD price for good purchases well below 2 for centred strength and precision. Assessment of a modified commercial approach and find for Talazoparib by ninety-nine.5%. For the approximation of pitavastatin in substance & medicine dose structures, an honest, clear, thorough, and precise turn around RP-HPLC was created and agreed. The symmetry ODS C18 (4,6 D250MM, 5µm) section using PDA discovery at 235 nm was completed with chromatographic partition of Pitavastatin. Methanol: Phosphate Buffer (35:65) v/v was the enhanced portable stage. The rate of flow was 1ml/min. At a maintenance time of 2.572 minutes. Chromatogram demonstrated the basic top. The approach is designed for linearity, precision, accuracy, location, measuring breaking point, heart rate and strength. The linearity was derived from the 6-14µg/ml focus range. The coefficient of regression was 0.999. Y=12035x–6630 was seen in the reciprocal situation. For the approximation of Pitavastatin, the most discovery and breaking point were found independently in 1.2µg/ml and 3.6µg/ml. Pitavastatin recovery was observed to be within the range of 100.72%. For quantifiable Pitavastatin assurance in bulk and pharmacological measurement structures, a proposed approach has been effectively used.

Keywords: Talazoparib, Pitavastatin, RP-HPLC

A R T I C L E I N F O

Corresponding Author
Dr. Agaiah Goud Bairi
Professor, Department of Pharmaceutics,
SRR College of Pharmaceutical Sciences, Telangana, India

A R T I C L E H I S T O R Y: Received 20 June 2022, **Accepted** 30 Aug 2022, **Available Online** 10 Oct 2022

Citation: *Agaiah Goud Bairi, et al. Method development and validation for the simultaneous estimation of Talazoparib and Pitavastatin in bulk and tablet dosage form by using RP-HPLC in biorelevant dissolution media. Int. J. Med. Pharm. Res., 2022, 10(1): 52-60.*

CONTENTS

1. Introduction

Most formulations include complicated mixes comprising a variety of inert components, such as diluents, disintegrants, colours and flavours, in addition to one or more medicinally active substances. These mixes should be divided into distinct components before qualitative examination to assure the quality and stability of the final product. The Chromatography technology for the resolution of these combinations is the most powerful. Characteristics which differentiate chromatography from most other chemical separation techniques are that two phases, one stationate and the other mobile, are put into contact. High-performance Liquid Chromatography (HPLC) provides for a wider range of stationary stages, allowing select interactions and more separation opportunities across different chromatographic techniques. The chromatographical separation column is the centre of the separation of ion, organic compounds, natural, polymeric and high-power polyfunctional substances.

2. Material and methods

Table-1: Materials used

S.no.	Instrument	Model
1	Hplc;	Software: Empower 2 Waters, Software: Alliance 2695 Sept.
2	PH meter;	Labindia
3	weighing ;machine	Sartorius
4	Volumetri; c flasks	Borosil
5	Pippetes and burettes	Borosil
6	Beakers;	Borosil
7	Digital; ltra sonicator	Enertech

Table-2: chemicals used

S.no	Chemical;	Brand Name
1	Talazoparib;	Pfizer pharma.india pvt.Ltd
2	Water and methanol for HPLC;	Lichrosolv(MERK)
3	Acetonitrile for HPLC;	Merk

Optimized chromatographic situations:

Tool used: Waters HPLC with automobile sampler & PDA detector 996 typical.

Temperature : 35°C

Column: Inertsil ODS C18 (four.6mm x 250mm, five µm)

Mobile Section: Methanol: Acetate Buffer (pH-four.2) (forty: 60 v/v)

Go with the waft price: 1.0ml/minute

Wavelength : 225 nm

Injection quantity : 10µl

Run time : 10minutes

Approach Validation

Steering of buffer and cellular phase:

Steerage Modern-Day Acetate Buffer (Ph-4.2): Prepare 800mL distilled water in a suitable situation. Upload 2.593 g cutting-cutting modern day Sodium Acetate (anhydrous) to the solution or upload four.106 g emblem new modern Acetic Acid to the solution. Adjust approach to very last preferred pH 4.2 the use of HCl or NaOH upload distilled water till quantity is 1 L.

Steering Mobile Section:

As it need to be measured four hundred ml (forty%) contemporary Methanol and six hundred ml cutting-cutting modern Acetate Buffer (60%) had been combined and degassed in a virtual ultra-sonicator for 10min & formerly filtered thru 0.45 µm easy out below vacuum filtration.

Diluent Steering: The cell segment used the reality the diluent.

Technique Confirmation Limitations

Suitability of Device

Successfully weigh & transfer 10mg reducing-modern Pitavastatin walking lowering-cutting modern-day- right into a 10ml reducing-cutting modern-day smooth dry volumetric flasks upload approximately 7mL cutting-cutting modern-day- Diluents & sonicate to liquefy it in fact & make amount on top modern-day-day day by the equal solvent. (Stock solution). Similarly pipe zero.1ml the overhead Pitavastatin inventory answer right proper right into a 10ml volumetric bottle & dilute on top by diluents.

Tool:

The answer have turned out to be introduced for 5 times and determined the region for all 5 injections in HPLC. The %RSD for the location day five replicate injections modified into placed to be in the focused restrictions.

Specificity:

Schooling Decreasing-Cutting modern Preferred Answer: Because it need to be weigh and transfer 10 mg modern-day-day Pitavastatin on foot fashionable proper right proper right proper right into a 10ml smooth desiccated volumetric containers upload approximately 7ml Diluents & sonicate to dissolve it actually & make amount on top by the matching solvent. (Stock Answer). Supplementary pipe zero.1ml slicing-current modern-day the above Pitavastatin stock answers right proper into a 10ml volumetric container& dilute on top emblem new modern with diluents.



Figure 1

Linearity: because it need to be weigh and switch 10 mg -day Pitavastatin strolling elegant right proper into a 10ml cutting-edge-day fresh waterless volumetric bottles add nearby 7ml appreciably-day Diluents & sonicate to liquefy it without a doubt & make amount on top -day with the equal solvent. (Stock Answer)

Education Lowering-Cutting Modern-Day Diploma – I (6ppm Pitavastatin): Take zero.6ml slicing-cutting modern-day inventory solution in to 10ml modern-day-day volumetric flask and make up the amount as hundreds as mark with diluents and sonicate the solution for bubble entrapment the usage of ultrasonicator. Education Reducing-cutting modern diploma – II (8ppm Pitavastatin): Take 0.8ml contemporary-day inventory answer in to 10ml volumetric bottle & make up the amount as hundreds as mark with diluents and sonicate the solution for bubble entrapment the usage of ultrasonicator.

Education degree – III (10ppm modern-day-day Pitavastatin):

Take 0.1ml modern-day-day inventory answer in to 10ml volumetric container & make up the amount as a bargain as mark with diluents and sonicate the answer for bubble entrapment the use of ultrasonicator.

Training Decreasing-cutting-modern degree – IV (12ppm cutting-modern Pitavastatin):

Take 0.12ml decreasing-present day modern inventory answer in to 10ml cutting-reducing-cutting modern-volumetric flask and make up the amount as hundreds as mark with diluents and sonicate the answer for bubble entrapment using ultrasonicator.

Steerage Diploma – V (14ppm Current-Day Pitavastatin):

Take 0.14ml cutting-edgemodern-day stock solution in to 10ml volumetric flask and make up the quantityas hundreds as mark with diluents and sonicate the solution for bubble entrapment the usage of ultrasonicator.

Method: Introduce every degree into the chromatographic device & diploma the height region. Plot a curve top area in desire to hobby (on X-axis interest & on Y-axis pinnacle region) &determine the coefficient of correlation.

Repeatability

Modern steering of cutting Product Pitavastatin Response to Precision: weight and switch 10 Mg of Pitavastatin Reducing Elegant Modern Cutting Footpit in a 10 Ml cutterday smooth volumetric flask upload approximately 7ml Extremely Sonic to License and add quantities to the same solvent. Pitavastatin Product Response to Precision: (Solution of the inventory)

Another zero pipette

Current 1ml cutting, straight down to a 10ml volume flask with the aforementioned Pitavastatin solutions and diluted with diluents on the most highest modern day. The huge response is injected into 5 cases and all 5 HPLC injections have been measured. The RSD percentage in the position 5 has been changed to be within the centred boundaries.

Intermediary correctness:

To evaluate the intermediate precision (moreover called roughness) on the approach today, precision is finished by the usage of the same conditions in exact days.

Approach:

Analyst 1: The trendy solution was injected six times and the area was determined for all 6 HPLC injections. Day-six display injections are selected to be inside superb limitations with the percent RSD for the site.

Analyst 2: The large response was six times injected and all six injections in HPLC were measured. The percentage RSD of six replicates was shown to be within excellent bounds for the region.

Accuracy:

For fifty percent favourite stock education answer: as it is intends, add around 7mL diluents and dissolve it to produce quantity at the top of the day by dissolving 10 mg -day- pitavastatic flasks well, in a specially- smooth dry volumetric flask. (Reply from the stock). The Pitavastatin inventory above also responds correctly to a 10 ml volumetric bottle on pinnacles today with diluents. Similarly the pipette is 0.05 ml daily.

Modern 100 percent stock solution for education reduction: As it wants to weigh and transfer 10 mg -day Pitavastatin walking, you want to load approximately 7 ml down-to-the-modern, smooth, dry and volumetric fibre Sonics & diluents to liquefy in reality and to produce amount using the same solvent on a pinnacle cutting current day. (Answer from the Stock)

Pipette 0 is also included

The aforementioned solution in inventory of Pitavastatin 1ml slicing-modern-day directly into a 10ml volumetric bottle and dilute with dilutes on today's top. Modern 100 fifty percent inventory solution for education reduction: if you want to weigh up and transfer 10 mg per day Pitavastatin well into a 10 ml clean dehydrated capacity container adds about 7mL /day for educational purposes Dilutes & sonicates to actually liquefy and add the brand-new contemporary pinnacle to the identical solvent. (Response to the inventory)

Pipette zero similarly.

15ml of Pitavastatin stock, which is present in the present day, responds properly in a 10ml flask and dilutes in modern pinnacle cutting with diluents.

Method: Under the optimum conditions, injections had been created of 3 duplicate injections lowering the cutting-

out modern-day concentrations in individual scenarios (50%, 100%, 150%). The chromatograms were documented and the height responses were computed. Measure further for Pitavastatin the quantity placed & measure distinct cure & healing qualities Measure.

3. Results and Discussion

Trails for the technique development:

Path 1:

Column : Phenomenex C18 (four.6×250mm) 5µm
Column temperature: 40°C
Wavelength: 235 nm
Cellular Section Ratio: ACN: Water (60:40) V/V
go along with the waft price : 1ml/min
Injection quantity : 10µl
Run time : nine.5min



Fig.2: Chromatogram for direction 1

Path 2:

Column : Devilosil C18 (four.6×250mm) fiveµm
Column temperature : 35°C
Wavelength : 235 nm
Cell segment ratio : Methanol: Water (70:30) V/V
go with the flow price : 1.0ml/min
Injection amount : 10µl
Run time : 10min



Fig.3: Chromatogram for direction 2

Optimized Chromatogram

Mobile phase ratio: Methanol: Phosphate Buffer (35: sixty five) V/V
Column : Symmetry ODS C18 (four.6×250mm, 5µm)
Column temperature : Ambient
Wavelength : 235 nm
go with the go together with the go together with the waft price: 1ml/min
Injection quantity : 10µl
Run time : 8min



Fig-4: Chromatogram Improved

Specificity Checks Drug Technical Valition Parameters:

Modern-Day Steering Response: Because it wants to weigh and turn 10mg contemporary Talazoparib into 10 ml modern-day smooth, dry volumetric containers and upload about 7 ml diluent for walking well-known correctly. Sonicate, then, to without certain liquefy and add the same solvent to the summit. (Reply from the stock). Similarly, 1 ml/day pipette, properly diluted with diluents, the above-mentioned Talazocolum stock solutions in a 10ml volumetric flask.



Fig-5: Specificity



Fig-6: Intermediary Strictness



Fig-7: Repeatability



Fig-9: Robustness chromatogram-2



Fig-8: Robustness chromatogram-1



Fig-10: Chromatogram for Improved (exquisite)

Table 1: Assay Standard Peak Consequences

S.No.	Name of Peak	RT	Area	Height	Plate Count	Tailing
1	Talazoparib	3.379	145857	32654	8546	1.76
2	Talazoparib	3.303	145874	32587	8574	1.77
3	Talazoparib	3.322	145685	32564	8759	1.76
4	Talazoparib	3.327	145876	32854	8598	1.76
5	Talazoparib	3.310	145682	32415	8564	1.77
Mean			145794.8			
Std.Dev.			101.8759			
%RSD			0.069876			

Table-2: Peak results for Assay sample

S.No.	Name	RT	Area	Height	USP tailing	USP Plate Count	Injection
1	Talazoparib	3.523	146425	32658	1.78	8457	1
2	Talazoparib	3.526	146874	32547	1.77	8495	2
3	Talazoparib	3.639	146524	32658	1.78	8475	3

Table-3: Chromatographic facts for Linearity test

Concentration g/ml	Average Peak Area
60	85784
80	112564
100	139867
120	165248
140	189586

Table-4: Repeatability Effects for Talazoparib

S. No.	Name of Peak	Retention time	Area	Height	Plate Count	Tailing
1	Talazopiarib	3.6349	1445865	342652	85447	1.478
2	Talazoiparib	3.6242	1445874	324541	84498	1.748
3	Talazoiparib	3.5475	1445842	324564	85447	1.477
4	Talazoiparib	3.5245	14445869	324548	84572	1.747

5	Talazioparib	3.5246	1445265	342569	84569	1.478
Mean			1445743			
Std. De4v			267.4911			
%R4SD			0.1483536			



Fig-11: Calibration Curve today's Talazoparib



Fig-12: LOD & LOQ for Talazoparib

Table-5: Outcomes tool aptness for Pitavastatin

S.No.	Name of Peak	Rt	Area	Height	USP Plate Count	Tailing USP
1	Pitavvastatin	2.5950	16525847	1855647	65589	1.254
2	Pitavavstatin	2.5753	16535658	1862554	65587	1.256
3	Pitavvastatin	2.5752	16545521	1855475	65584	1.258
4	Pitavvastatin	2.5750	16553564	1865594	65582	1.529
5	Pitavvastatin	2.5573	16558745	1856584	68955	1.524
Meavn			16546567			
Std.vDev.			235555.764			
%RSvD			0.1425371			

Table 6: records for Linearity -day Pitavastatin

Concentration g/ml	Average Peak Area
6	1078475
8	1461129
10	1808358
12	2211573
14	2593778



Fig-13: Linearity Curve present day- Pitavastatin

Table-7: Pitavastatin repetitiveness outcomes

S. No.	Name of Peak	Rt	Area	Height	Plate Count	Tailing
1	Pitavastatin	2.572	1658954	186958	1.26	6785
2	Pitavastatin	2.570	1658745	187548	1.27	6854
3	Pitavastatin	2.573	1659865	189854	1.26	6852
4	Pitavastatin	2.570	1653254	186985	1.25	6784
5	Pitavastatin	2.574	1654781	189542	1.24	6895
Mean			1657120			
Std. Dev			2913.592			
%RSD			0.175823			

Table-8: effects Intermediary precision for Pitavastatin

S.No.	Name of Peak	Rt	Area	Height	Plate Count USP	Tailing USP
1	Pitavastatin	2.573	1678541	186589	6587	1.26

2	Pitavastatin	2.574	1685985	186598	6321	1.26
3	Pitavastatin	2.570	1685745	186985	6385	1.25
4	Pitavastatin	2.573	1685987	187854	6580	1.26
5	Pitavastatin	2.570	1698526	187549	6721	1.27
6	Pitavastatin	2.572	1685943	186598	6637	1.26
Mean			1686788			
Std.Dev.			6463.466			
%RSD			0.383182			

Table-9: The accurateness consequences for Pitavastatin

%Attentiveness (at measurement Level)	Area of Peak	Quantity Additional (ppm)	Extent Establish (ppm)	% Regaining	Average Recovery
50%	109068.3	5	5.021	100.420%	100.72%
100%	202187	10	10.054	100.540%	
150%	297032.3	15	15.181	101.206%	



Fig-14: Acid Degradation modern-day Talazoparib Chromatogram



Fig-15: Oxidative Degradation present day-day day Talazoparib Chromatogram



Fig-16: Alkaon-Degradation modern-day Talazoparib Chromatogram



Fig-17: Photolytic Degradation Talazoparib Chromatogram

Table-10: Consequences present day pressured Degradation research for Talazoparib

S.No.	Stress Condition	Peak Area	% of Degraded Amount	% of Active Amount	Total % of Amount
1	Standard	145867.00	0	100%	100%
2	Acidic	112259.24	23.04	76.96	100%
3	Basic	124687.11	14.48	85.48	100%
4	Oxidative	133803.79	8.27	91.73	100%
5	Thermal	136341.88	6.53	93.47	100%
6	Photolytic	134956.14	7.48	92.52	100%



Fig-18: Alkaon-Degradation present day Pitavastatin Chromatogram



Fig-19: Thermal Degradation cutting-modern-day Pitavastatin Chromatogram



Fig-20: Oxidative Degradation current day Pitavastatin Chromatogram



Fig-21: Photolytic Degradation Pitavastatin Chromatogram

Table-11: consequences present day pressured Degradation research for Pitavastatin

Condition of Stress	Period	Active substance Assay	Degraded products Assay	Balance of Mass (%)
Hydrolysis of Acid (0.1 M HCl)	24Hrs.	83.64	16.36	100.0
Basic Hydrolysis (0.I M NaOH)	24Hrs.	84.69	15.31	100.0
Thermal Degradation (50 ^{0}C)	24Hrs.	87.85	12.15	100.0
UV (254nm)	24Hrs.	98.47	1.53	100.0
3 % Hydrogen peroxide	24Hrs.	96.64	3.36	100.0

4. Conclusion

The analytical method have end up superior via reading particular parameters. To start with, most absorbance became decided to be at 225 nm & the peak purity modified into. Injection amount modified into decided straight away to be 10µl which gave an amazing top location. The column used for test grow to be Inertsil ODS C18 (four.6mm x 250mm, 5mm) as it changed into giving right top. 35°C temperature changed into placed to be appropriate for the person of medication solution. For quantitatively evaluating Talazoparib in the administrative centre art work API & pharmacological quantity, a smooth, sensitive, distinctive and accurate RP-HPLC technique has become superior in the current investigation. This technique has been adjusted to be clean, because the diluted samples are utilised immediately without any first derivative chemical or purification procedures. Talazoparib has become soluble in natural solvents that contain ethanol, dimethyl formamide and water solvable, DMSO and acetonitrile, and its miles of dichloromethanes that are free of any problems, carefully soluble in ethyl alcohol.

For the assessment of Pitavastatin in pill measuring systems, a unique, clean, particular, exact, and specific RP-HPLC technique has been developed and is now standard. Pitavastatin was separated chromatographically on a C18 (4.6250mm,5m) Symmetry segment. The enhanced adaptability level was changed to Methanol: Phosphate Buffer (35:65) v/v. The gliding rate was reduced to 1 ml/min, and the analytes were detected at 235 nm. The developed method was successfully used to estimate Pitavastatin quantitatively in pill dimension systems.

5. References

[1] "Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S." (Press release). Takeda Pharmaceutical Company. January 4, 2008. Retrieved January 9, 2008.

[2] Feng, Jun; Zhang, Zhiyuan; "Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV". J. Med. Chem. 50 (10): 2297–2300.

[3] Anusha Tiyyagura et al, Method Development and Validation for The Simultaneous Estimation of Glecaprevir and Pitavastatin in Pharmaceutical Dosage form by RP-HPLC, IJPCBS, 2017, 3(1), 44-54.

[4] "ACTOS (pioglitazone) Prescribing Information" (PDF). United States Food and Drug Administration. November 2013.

[5] M. Sathish Kumar, B. Sandhya Rani, N. Mounika, J. Mamatha, J. Kranthi Kumar, A Validated RP-HPLC Method for the Simultaneous Estimation of Atazanavir and Ritonavir in Pharmaceutical Dosage Forms, ARC Journal of Pharmaceutical Sciences, Volume 2, Issue 1, 2016, PP 21-31.

[6] Kranthikumar V, Sundaraganapathy R, et al., Development and Validation of RP-HPLC Method for simultaneous estimation of Domperidone and Lafutidine in Pharmaceutical Tablet Dosage Form, International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 5, Issue 2, 2013.

[7] Mohammad Yunoos, M. Sowjanya, B. Sushma, K. Pavan Kumar. A Validated Simple UV Spectrophotometric Method for the Estimation of Pitavastatin in bulk and Pharmaceutical Dosage Form. Asian J. Research Chem. 7(4): 2014, 393-396.

[8] Maryam Bavand Savadkouhi et al, RP-HPLC Method Development and Validation for Determination of Eptifibatide Acetate in Bulk Drug Substance and Pharmaceutical Dosage Forms, Iran J Pharm Res. 2017 16(2): 490–497.